| Tresiba (insulin degludec) / Novo Nordisk |
ChiCTR1900028213: Phase I, Randomized, Open-label, Single-dose, Two-phase, Cross-over trial for pharmacokinetics, pharmacodynamics and safety evaluation of Insulin Degludec Injection and TRESIBA produced from Novo Nordisk in Chinese healthy subjects |
|
|
| Not yet recruiting | 1 | 32 | | Phase I: TRESIBA produced from Novo Nordisk; Phase II: Insulin Degludec Injection ;Phase I: Insulin Degludec Injection; Phase II: TRESIBA produced from Novo Nordisk | West China Hospital, Sichuan University; Jilin Huisheng Biopharmaceutical Co., Ltd., Sponsor | Diabetes Mellitus | | | | |
ChiCTR2100043751: A randomized, open, two-period, self-cross-control design, using glucose clamp technology to evaluate the pharmacokinetics, pharmacodynamics and safety of insulin degludec injection and |
|
|
| Recruiting | 1 | 28 | | TR ;RT | The Second Affiliated Hospital of Xingtai Medical College; Zhuhai United Laboratories Co., None | For the treatment of adult type 2 diabetes | | | | |
NCT06556641: A Clinical Study of GZR33 and GZR101 in Healthy Subjects |
|
|
| Completed | 1 | 28 | RoW | GZR33 Injection, GZR101 Injection, Placebo, Insulin Degludec | Gan and Lee Pharmaceuticals, USA | Healthy Subjects | 02/23 | 02/23 | | |
NCT06553248: A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes |
|
|
| Completed | 1 | 36 | RoW | GZR4, Insulin Degludec | Gan and Lee Pharmaceuticals, USA | Diabetes | 11/23 | 11/23 | | |
NCT06132126: A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 66 | US | LY3938577, Placebo, Insulin degludec | Eli Lilly and Company | Healthy, Type 2 Diabetes Mellitus | 06/24 | 06/24 | | |
NCT06288412: A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting |
|
|
| Recruiting | 1 | 30 | Europe | Insulin icodec, Insulin degludec | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 11/24 | 11/24 | | |
NCT06280703: A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) |
|
|
| Recruiting | 1 | 70 | Europe | LY3938577, Placebo, Insulin Degludec, Insulin Lispro | Eli Lilly and Company | Healthy, Type 1 Diabetes Mellitus | 02/25 | 02/25 | | |
